TFF Pharmaceuticals Inc (TFFP) Stock Overview
USA - NASDAQ:TFFP - US87241J2033 - Common Stock
TFFP Key Statistics, Chart & Performance
The current stock price of TFFP is 0.065 USD. In the past month the price decreased by -96.13%. In the past year, price decreased by -99.17%.
TFFP Latest News, Press Relases and Analysis
TFFP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.78 | 776.19B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.61 | 256.13B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.95 | 238.94B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.38 | 231.28B | ||
| MRK | MERCK & CO. INC. | 11.3 | 217.38B | ||
| PFE | PFIZER INC | 7.23 | 139.30B | ||
| SNY | SANOFI-ADR | 11.55 | 124.44B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.36 | 87.16B | ||
| GSK | GSK PLC-SPON ADR | 9.75 | 87.89B | ||
| ZTS | ZOETIS INC | 23.38 | 64.44B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.36 | 44.53B |
Related stock screener links
About TFFP
Company Profile
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Company Info
TFF Pharmaceuticals Inc
2600 Via Fortuna Ste 360
Austin TEXAS 78746 US
CEO: Glenn Mattes
Employees: 19
Phone: 17378021973
TFF Pharmaceuticals Inc / TFFP FAQ
What does TFFP do?
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
What is the stock price of TFF Pharmaceuticals Inc today?
The current stock price of TFFP is 0.065 USD. The price decreased by -60.05% in the last trading session.
Does TFFP stock pay dividends?
TFFP does not pay a dividend.
How is the ChartMill rating for TFF Pharmaceuticals Inc?
TFFP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
TFFP Technical Analysis
TFFP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TFFP. The financial health of TFFP is average, but there are quite some concerns on its profitability.
TFFP Financial Highlights
Over the last trailing twelve months TFFP reported a non-GAAP Earnings per Share(EPS) of -6.44. The EPS increased by 50.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| Debt/Equity | 0 |
TFFP Forecast & Estimates
7 analysts have analysed TFFP and the average price target is 30.6 USD. This implies a price increase of 46976.92% is expected in the next year compared to the current price of 0.065.
For the next year, analysts expect an EPS growth of 65.1% and a revenue growth 60.13% for TFFP